Gottlieb: The Next Janet Woodcock Is Waiting To Be Discovered At FDA
Executive Summary
In interview with the Pink Sheet, US FDA Commissioner says the agency needs new ways for in-house talent to more easily rise to supervisory and executive levels.
You may also be interested in...
US FDA CDER, CBER Staff Say Pandemic Had Negative Effect On Hiring, Retention
Human resource managers also worried that since universal teleworking was valued by employees, a return to pre-pandemic conditions could cause a mass exodus.
GDUFA III Calculation Faces Rising Staff Costs
After dialing back the inflation adjustment in GDUFA II, FDA’s ANDA review program now faces rising personnel costs, in contrast to the agency overall, suggesting that GDUFA III might need a more tailored formula.
Generic Drug User Fee Projections Complicated By Shifting Personnel Costs
After dialing back the inflation adjustment in GDUFA II, FDA’s ANDA review program now faces rising personnel costs, in contrast to the agency overall, suggesting that GDUFA III might need a more tailored formula.